Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical experience with simvastatin compared with cholestyramine.

D W Erkelens1, M G Baggen, J J Van Doormaal

  • 1Department of Internal Medicine, University Hospital, Utrecht, The Netherlands.

Drugs
|January 1, 1988
PubMed
Summary

Simvastatin effectively lowers LDL cholesterol in familial hypercholesterolemia patients, outperforming cholestyramine. Combining simvastatin with cholestyramine offers even greater cholesterol reduction with manageable side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mental Health in Familial Adenomatous Polyposis: A Systematic Review.

Psycho-oncology·2025
Same author

Correspondence regarding "Suicide trends in Germany during the COVID-19 pandemic and the war in Ukraine" by D. Radeloff et al.

Psychiatry research·2024
Same author

Comparison of all completed suicides in Frankfurt am Main (Hessen) before and during the early COVID-19 pandemic.

Forensic science, medicine, and pathology·2023
Same author

Respiratory viruses in medicolegal autopsies during the winter season 2021/2022: observations after reduction of coronavirus disease-19 (COVID-19) pandemic restrictions.

International journal of legal medicine·2023
Same author

[Spinal arteriovenous malformations].

Radiologie (Heidelberg, Germany)·2022
Same author

Detection and infectivity of SARS-CoV-2 in exhumated corpses.

International journal of legal medicine·2021

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Biochemistry

Background:

  • Familial hypercholesterolemia is a genetic disorder characterized by high LDL cholesterol levels.
  • Hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors are a class of drugs used to lower cholesterol.
  • Simvastatin is a potent HMG CoA reductase inhibitor derived from lovastatin.

Purpose of the Study:

  • To compare the efficacy of simvastatin with cholestyramine in lowering LDL cholesterol.
  • To evaluate the combined effect of simvastatin and cholestyramine.
  • To assess the impact on other lipid parameters and adverse effects.

Main Methods:

  • A study involving patients with heterozygous familial hypercholesterolemia.
  • Comparison of simvastatin monotherapy, cholestyramine monotherapy, and combination therapy.

Related Experiment Videos

  • Monitoring of LDL cholesterol, total cholesterol, HDL cholesterol, triglycerides, and apolipoprotein ratios.

    • Main Results:

    • Simvastatin reduced LDL cholesterol by 43%, compared to 30% with cholestyramine.
    • Combination therapy resulted in a 54% reduction in LDL cholesterol.
    • Simvastatin also improved total cholesterol, HDL cholesterol, triglyceride levels, and the apolipoprotein B/A ratio, with fewer gastrointestinal side effects than cholestyramine.

    Conclusions:

    • Simvastatin is more effective than cholestyramine in lowering LDL cholesterol and reduces atherogenic plasma potential with fewer adverse effects.
    • Combination therapy provides superior lipid-lowering effects for patients tolerating cholestyramine.
    • Simvastatin represents a potent therapeutic option for managing familial hypercholesterolemia.